Editas Medicine (EDIT) Competitors $2.44 +0.07 (+2.95%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends EDIT vs. ADVM, CLLS, BLUE, DTIL, SGMO, CRON, PLRX, KURA, TYRA, and PRTAShould you be buying Editas Medicine stock or one of its competitors? The main competitors of Editas Medicine include Adverum Biotechnologies (ADVM), Cellectis (CLLS), bluebird bio (BLUE), Precision BioSciences (DTIL), Sangamo Therapeutics (SGMO), Cronos Group (CRON), Pliant Therapeutics (PLRX), Kura Oncology (KURA), Tyra Biosciences (TYRA), and Prothena (PRTA). These companies are all part of the "medical" sector. Editas Medicine vs. Adverum Biotechnologies Cellectis bluebird bio Precision BioSciences Sangamo Therapeutics Cronos Group Pliant Therapeutics Kura Oncology Tyra Biosciences Prothena Editas Medicine (NASDAQ:EDIT) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations, risk and community ranking. Do insiders and institutionals have more ownership in EDIT or ADVM? 71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are owned by institutional investors. 1.9% of Editas Medicine shares are owned by company insiders. Comparatively, 4.2% of Adverum Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has higher valuation and earnings, EDIT or ADVM? Adverum Biotechnologies has lower revenue, but higher earnings than Editas Medicine. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEditas Medicine$61.76M3.26-$153.22M-$2.56-0.95Adverum Biotechnologies$1M125.64-$117.17M-$5.99-1.01 Do analysts recommend EDIT or ADVM? Editas Medicine presently has a consensus target price of $9.08, indicating a potential upside of 272.27%. Adverum Biotechnologies has a consensus target price of $27.83, indicating a potential upside of 360.82%. Given Adverum Biotechnologies' stronger consensus rating and higher probable upside, analysts plainly believe Adverum Biotechnologies is more favorable than Editas Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Editas Medicine 0 Sell rating(s) 6 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.54Adverum Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Does the MarketBeat Community prefer EDIT or ADVM? Adverum Biotechnologies received 58 more outperform votes than Editas Medicine when rated by MarketBeat users. Likewise, 60.39% of users gave Adverum Biotechnologies an outperform vote while only 53.81% of users gave Editas Medicine an outperform vote. CompanyUnderperformOutperformEditas MedicineOutperform Votes31153.81% Underperform Votes26746.19% Adverum BiotechnologiesOutperform Votes36960.39% Underperform Votes24239.61% Is EDIT or ADVM more profitable? Adverum Biotechnologies has a net margin of 0.00% compared to Editas Medicine's net margin of -340.96%. Adverum Biotechnologies' return on equity of -65.14% beat Editas Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Editas Medicine-340.96% -80.13% -50.99% Adverum Biotechnologies N/A -65.14%-40.52% Which has more volatility and risk, EDIT or ADVM? Editas Medicine has a beta of 2.01, indicating that its stock price is 101% more volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Does the media refer more to EDIT or ADVM? In the previous week, Adverum Biotechnologies had 6 more articles in the media than Editas Medicine. MarketBeat recorded 12 mentions for Adverum Biotechnologies and 6 mentions for Editas Medicine. Adverum Biotechnologies' average media sentiment score of 0.64 beat Editas Medicine's score of 0.64 indicating that Adverum Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Adverum Biotechnologies 3 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAdverum Biotechnologies beats Editas Medicine on 12 of the 18 factors compared between the two stocks. Ad Brownstone ResearchBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.I believe we are about to do it again with this new AI project called Stargate Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDIT vs. The Competition Export to ExcelMetricEditas MedicineBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$201.42M$3.04B$5.20B$8.83BDividend YieldN/A1.91%5.06%4.09%P/E Ratio-0.9542.69112.7217.51Price / Sales3.26352.371,242.97159.41Price / CashN/A169.3839.8636.27Price / Book1.154.597.056.49Net Income-$153.22M-$41.63M$118.72M$225.45M7 Day Performance-8.27%2.49%2.20%3.61%1 Month Performance-25.84%-3.43%-3.08%3.45%1 Year Performance-76.74%28.39%33.70%29.16% Editas Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDITEditas Medicine4.7036 of 5 stars$2.44+3.0%$9.08+272.3%-76.7%$201.42M$61.76M-0.95230Analyst RevisionADVMAdverum Biotechnologies4.1174 of 5 stars$5.80-6.0%$27.83+379.9%-28.1%$128.35M$1M-0.97190Analyst ForecastHigh Trading VolumeCLLSCellectis2.8671 of 5 stars$1.87-2.1%$7.00+274.3%-33.3%$106.17M$29.07M-1.44290Analyst ForecastBLUEbluebird bio2.4989 of 5 stars$0.29-3.3%$3.03+926.8%-90.8%$57.28M$29.50M-0.16323DTILPrecision BioSciences4.043 of 5 stars$6.50-9.5%$39.50+507.7%-42.9%$49.86M$48.73M109.02200High Trading VolumeSGMOSangamo Therapeutics2.16 of 5 stars$1.97+1.0%$7.00+255.5%+424.7%$410.87M$176.23M-2.63480CRONCronos Group1.8238 of 5 stars$2.05+2.0%$3.00+46.3%+4.0%$783.72M$87.24M-15.46356PLRXPliant Therapeutics3.4996 of 5 stars$12.85+0.9%$40.57+215.7%-6.8%$781.92M$1.58M-3.8590KURAKura Oncology4.0734 of 5 stars$10.00-37.1%$29.43+194.3%+15.0%$777.68MN/A-4.45142Analyst ForecastNews CoverageGap UpHigh Trading VolumeTYRATyra Biosciences2.9438 of 5 stars$15.36-3.2%$31.00+101.8%+38.7%$777.22MN/A-9.6220PRTAProthena1.6559 of 5 stars$14.44+0.3%$61.86+328.4%-55.4%$777.02M$91.37M-5.82173Analyst Downgrade Related Companies and Tools Related Companies Adverum Biotechnologies Competitors Cellectis Competitors bluebird bio Competitors Precision BioSciences Competitors Sangamo Therapeutics Competitors Cronos Group Competitors Pliant Therapeutics Competitors Kura Oncology Competitors Tyra Biosciences Competitors Prothena Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EDIT) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EDIT Stock Alerts